The Global Health Body Sounds Warning Over Acute Scarcity of Obesity Injections
Fewer than 10% of people who could benefit from obesity jabs such as Wegovy can access them, warns the WHO as it issues its inaugural advice on the drugs.
With in excess of 1,000,000,000 people worldwide now living with obesity, it is urging increased and just availability to these injectable treatments.
Based on forecasts, over two billion could be living with obesity by 2030 if no action is taken.
"The new guidelines affirms that obesity is a lifelong illness that can be addressed with comprehensive and ongoing support," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are significant obstacles to universal availability to the treatments that can aid individuals in losing significant weight, says the body.
GLP-1 Therapy Supply Crisis
Even in the current most optimistic case, the supply of these medications might only reach around 100 million people – fewer than 10% of the global need, as stated by the WHO.
The advice urges governments and firms to widen access, through measures including voluntary licensing.
Exclusive production rights on the active ingredient – the primary component of Novo Nordisk's Wegovy – is scheduled to end in several countries in 2026.
How Obesity Jabs Operate
The injections mimick a natural hormone to reduce digestion speed, suppress the appetite and enhance feelings of fullness so users consume fewer calories.
Patients typically begin shedding pounds after several weeks of starting on the regular doses.
Research indicates patients may see weight return a year later of halting the drug, as their typical hunger return.
To be carrying excess weight increases your likelihood for contracting medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity concerns people in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, according to the health agency.
